Lupin launches generic fenofibric acid capsules

R. Yegya Narayanan Coimbatore | Updated on March 12, 2018 Published on December 06, 2013

Lupin Ltd’s US subsidiary, Lupin Pharmaceuticals, Inc. (LPI), has launched the generic fenofibric acid delayed release capsules in 45 mg and 135 mg strengths.

These are the generic equivalent of AbbVie Inc.’s Trilipix indicated as co‐administration therapy with statins for the treatment of mixed dyslipidemia, treatment of severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia.

Trilipix delayed release capsules had yearly sales of around $449.5 million in the US, Lupin said in its filings with the stock exchanges.

The Lupin stock was up by Rs 11.40 to Rs 866.80 on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on December 06, 2013
This article is closed for comments.
Please Email the Editor